Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

AstraZeneca

1,649.50 SEK

+0.15 %

Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+0.15 %
-3.17 %
-3.11 %
+6.28 %
+11.23 %
+7.08 %
+21.55 %
+91.82 %
+8,925.74 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.56T SEK
Turnover
301.51M SEK
Revenue
596.39B
EBIT %
18.5 %
P/E
32.94
Dividend yield-%
2.07 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10/2
2026

Annual report '25

29/4
2026

Interim report Q1'26

All
Press releases
ShowingAll content types
Press releaseyesterday

AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals

AstraZeneca
Press releaseyesterday

AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines

AstraZeneca
Press release1/20/2026, 7:05 AM

AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release1/8/2026, 7:00 AM

AstraZeneca appoints Joris Silon as Head of Investor Relations

AstraZeneca
Press release1/6/2026, 7:00 AM

AstraZeneca: Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity

AstraZeneca
Press release12/22/2025, 7:30 AM

AstraZeneca: Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

AstraZeneca
Press release12/22/2025, 7:00 AM

AstraZeneca: Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer

AstraZeneca
Press release12/16/2025, 7:10 AM

AstraZeneca: Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus

AstraZeneca
Press release12/16/2025, 7:07 AM

AstraZeneca: Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

AstraZeneca
Regulatory press release12/4/2025, 8:22 AM

Finansinspektionen: Flaggningsmeddelande i AstraZeneca PLC

AstraZeneca
Press release12/4/2025, 7:13 AM

AstraZeneca advances haematology and cell therapy ambition with largest-ever presence at ASH

AstraZeneca
Press release12/2/2025, 7:31 AM

AstraZeneca: Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

AstraZeneca
Press release11/26/2025, 7:01 AM

AstraZeneca: Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers

AstraZeneca
Press release11/24/2025, 7:01 AM

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth

AstraZeneca
Press release11/20/2025, 7:00 AM

AstraZeneca: Koselugo approved in the US for adults with neurofibromatosis type 1

AstraZeneca
Regulatory press release11/20/2025, 7:00 AM

AstraZeneca: Koselugo (selumetinib) approved in the US

AstraZeneca
Regulatory press release11/17/2025, 8:02 AM

Finansinspektionen: Flaggningsmeddelande i AstraZeneca PLC

AstraZeneca
Press release11/10/2025, 7:06 AM

AstraZeneca: Bax24 Phase III Trial Full Results

AstraZeneca
Press release11/10/2025, 7:00 AM

Regeringen, AstraZeneca, Scania och RISE i nytt samarbete kring grön teknik

AstraZeneca
Regulatory press release11/6/2025, 7:00 AM

Resultat för AstraZeneca: 9 månader samt tredje kvartalet 2025

AstraZeneca
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.